ADVENTIST HEALTH GLENDALE
- Type
- Teaching hospital
- Where
- Glendale, CA
- Medicare CCN
- 050239
- Received
- $832,635 in 63 records, 2024 ($18,865 general, $813,770 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 3 | $18,865 |
| 2024 | Research payment | 60 | $813,770 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 18 | $534,336 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $152,288 | 2024 |
| Janssen Research & Development, LLC | 27 | $65,062 | 2024 |
| Genentech, Inc. | 3 | $27,359 | 2024 |
| Premia Spine, Ltd. | 5 | $21,748 | 2024 |
| AngioDynamics, Inc. | 1 | $13,000 | 2024 |
| Dilon Technologies, Inc. | 5 | $11,975 | 2024 |
| Aesculap Implant Systems, LLC | 1 | $3,900 | 2024 |
| Stryker Corporation | 1 | $1,965 | 2024 |
| Cerapedics Inc. | 1 | $1,000 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 60 | $813,770 |
| Long term medical supply or device loan | 2 | $14,965 |
| Debt forgiveness | 1 | $3,900 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,965 | Long term medical supply or device loan | In-kind items and services | SDC3 Device, ENDOSCOPY | 2024 | |
| 2024-12-18 | Janssen Research & Development, LLC | $2,037 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-12-16 | Janssen Research & Development, LLC | $798 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-12-11 | Janssen Research & Development, LLC | $920 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-11-21 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-11-21 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-11-18 | Janssen Research & Development, LLC | $1,844 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-11-08 | PFIZER INC. | $1,714 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-10-26 | PFIZER INC. | $9,162 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2024 |
| 2024-10-21 | Janssen Research & Development, LLC | $3,746 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-10-18 | Janssen Research & Development, LLC | $2,448 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-10-16 | PFIZER INC. | $150 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-10-05 | PFIZER INC. | $22,370 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-09-25 | Janssen Research & Development, LLC | $2,642 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-09-20 | Janssen Research & Development, LLC | $530 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-09-13 | Janssen Research & Development, LLC | $2,543 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-08-29 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-08-29 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-08-28 | PFIZER INC. | $2,219 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-08-23 | Janssen Research & Development, LLC | $4,346 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-08-22 | Genentech, Inc. | $4,050 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | 2024 |
| 2024-08-21 | Janssen Research & Development, LLC | $1,115 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-08-05 | Cerapedics Inc. | $1,000 | Research payment | Cash or cash equivalent | I-FACTOR PEPTIDE ENHANCED BONE GRAFT Device, PEPTIDE ENHANCED BONE GRAFT | Aspire Trial | 2024 |
| 2024-07-24 | Janssen Research & Development, LLC | $4,975 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-07-09 | Genentech, Inc. | $20,081 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TIRA PLUS ATEZO IN ADJUVANT NSCLC | 2024 |
| 2024-07-01 | Premia Spine, Ltd. | $3,781 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2024 |
| 2024-07-01 | Premia Spine, Ltd. | $50 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2024 |
| 2024-06-25 | Janssen Research & Development, LLC | $992 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-06-19 | Janssen Research & Development, LLC | $3,831 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-06-07 | Janssen Research & Development, LLC | $1,115 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-06-03 | Janssen Research & Development, LLC | $886 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-05-29 | PFIZER INC. | $2,018 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-05-28 | PFIZER INC. | $59,240 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-05-28 | PFIZER INC. | $59,240 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-05-26 | PFIZER INC. | $59,240 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-05-22 | Janssen Research & Development, LLC | $5,473 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-04-30 | PFIZER INC. | $911 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-04-19 | Janssen Research & Development, LLC | $2,130 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-04-15 | Janssen Research & Development, LLC | $1,666 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-04-15 | Premia Spine, Ltd. | $1,204 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2024 |
| 2024-04-08 | Janssen Research & Development, LLC | $1,593 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-04-02 | PFIZER INC. | $7,053 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-03-22 | Janssen Research & Development, LLC | $8,363 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-03-22 | Dilon Technologies, Inc. | $3,375 | Research payment | Cash or cash equivalent | MARGINPROBE PROBE Device, MARGIN ASSESSMENT | MarginProbe 2.0 Data Collection Protocol | 2024 |
| 2024-03-14 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-03-14 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-03-14 | PFIZER INC. | $44,430 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-03-13 | Janssen Research & Development, LLC | $394 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-03-06 | Janssen Research & Development, LLC | $224 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-02-21 | Janssen Research & Development, LLC | $1,596 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-02-16 | Dilon Technologies, Inc. | $950 | Research payment | Cash or cash equivalent | MARGINPROBE PROBE Device, MARGIN ASSESSMENT | MarginProbe 2.0 Data Collection Protocol | 2024 |
| 2024-02-15 | Dilon Technologies, Inc. | $3,775 | Research payment | Cash or cash equivalent | MARGINPROBE PROBE Device, MARGIN ASSESSMENT | MarginProbe 2.0 Data Collection Protocol | 2024 |
| 2024-02-14 | Aesculap Implant Systems, LLC | $3,900 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-02-12 | Genentech, Inc. | $3,228 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | T DM1 Atezolizumab in high risk HER2 patients with residual disease | 2024 |
| 2024-02-02 | Dilon Technologies, Inc. | $1,350 | Research payment | Cash or cash equivalent | MARGINPROBE PROBE Device, MARGIN ASSESSMENT | MarginProbe 2.0 Data Collection Protocol | 2024 |
| 2024-02-02 | Janssen Research & Development, LLC | $784 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-01-30 | Novartis Pharmaceuticals Corporation | $152,288 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2024 | |
| 2024-01-25 | Dilon Technologies, Inc. | $2,525 | Research payment | Cash or cash equivalent | MARGINPROBE PROBE Device, MARGIN ASSESSMENT | MarginProbe 2.0 Data Collection Protocol | 2024 |
| 2024-01-22 | Janssen Research & Development, LLC | $7,532 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-01-12 | Janssen Research & Development, LLC | $539 | Research payment | Cash or cash equivalent | 70033093STR3001 | 2024 | |
| 2024-01-04 | Premia Spine, Ltd. | $7,754 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2024 |
| 2024-01-02 | Premia Spine, Ltd. | $8,958 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Glendale, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) Glendale, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 190,748 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 196,543 | 10,014,009 | 39,538,223 |
| Median age B01002 | 41.4 | 38.2 | 37.9 |
| Under 18 B01001 | 18.4% | 20.6% | 22.0% |
| 65 and over B01001 | 19.0% | 15.2% | 15.7% |
| Households B11001 | 72,573 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 51.5% | 33.4% | 27.0% |
| Median household income B19013 | $88,393 | $90,112 | $99,122 |
| Median family income B19113 | $102,513 | $101,573 | $113,346 |
| Per capita income B19301 | $49,653 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.3% | 7.3% | 6.6% |
| Civilian labor force B23025 | 100,592 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 47.2% | 36.0% | 37.1% |
| Housing units B25001 | 77,783 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 35.2% | 45.9% | 55.9% |
| Renters B25003 | 64.8% | 54.1% | 44.1% |
| Median home value B25077 | $1,102,300 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,182 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 62.8% | 24.7% | 33.8% |
| Black B03002 | 1.4% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 18.1% | 48.4% | 40.2% |
| Asian B03002 | 12.8% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Glendale, CA.
Comments